Mometasone furoate nasal spray in Italian children with seasonal allergic rhinitis: a comprehensive assessment
Main Article Content
Keywords
mometasone furoate nasal spray, nasal cytology, quality of life, seasonal allergic rhinitis, symptoms, type 2 inflammation
Abstract
Objective: Seasonal allergic rhinitis (SAR) is a common disease of childhood and is characterized by type 2 inflammation, bothersome symptoms, and impaired quality of life (QoL). Intranasal corticosteroids are effective medications in managing SAR. In addition, mometasone furoate nasal spray (MFNS) is a well-known therapeutic option. However, the literature provided no data about the effects of MFNS in European children with SAR. Thus, this study addressed this unmet requirement.
Methods: MFNS was compared to isotonic saline. Both treatments were prescribed: one drop of spray per nostril, twice a day, for 3 weeks. Nasal cytology, total symptom score (TSS), visual analogic scale concerning the parental perception of severity of symptoms, and the Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ) were assessed at baseline, after 7 and 21 days, and 1 month after discontinuation.
Results: MFNS significantly reduced eosinophil and mast cell counts, improved QoL, and relieved symptoms, as assessed by doctors and perceived by parents. These effects persisted over time, even after discontinuation. Both treatments were safe and well-tolerated.
Conclusions: The present study documented that a 3-week MFNS treatment was able to significantly dampen type 2 inflammation, improve QoL, and reduce severity of symptoms in Italian children with SAR, and was safe.
References
2. Wen T, Rothenberg ME. Cell-by-cell deciphering of T cells in allergic inflammation. J Allergy Clin Immunol. 2019;144:1143–8. 10.1016/j.jaci.2019.10.001
3. Han X, Krempski JW, Nadeau K. Advances and novel developments in mechanisms of allergic inflammation. Allergy. 2020;75(12):3100–11. 10.1111/all.14632
4. Ciprandi, G, Klersy C, Cirillo I, Marseglia GL. Quality of life in allergic rhinitis: Relationship with clinical, immunological, and functional aspects. Clin Exp Allergy. 2007;37:1528–35. 10.1111/j.1365-2222.2007.02809.x
5. Ciprandi G, Cirillo I, Vizzaccaro A, Milanese M, Tosca MA. Nasal obstruction in patients with seasonal allergic rhinitis: Relationships between allergic inflammation and nasal airflow. Intern Arch Allergy Immunol. 2004;134:34–40. 10.1159/000077531
6. Cirillo I, Marseglia GL, Klersy C, Ciprandi G. Allergic patients have more numerous and prolonged respiratory infections than nonallergic subjects. Allergy. 2007;62:1087–90. 10.1111/j.1398-9995.2007.01401.x
7. Juel-Berg N, Darling P, Bolvig J, Foss-Skiftesvik MH, Halken S, Winther L, et al. Intranasal corticosteroids compared with oral antihistamines in allergic rhinitis: A systematic review and meta-analysis. Am J Rhinol Allergy. 2017;31(1):19–28. 10.2500/ajra.2016.30.4397
8. Baldwin CM, Scott LJ. Mometasone furoate: A review of its intranasal use in allergic rhinitis. Drugs. 2008;68(12):1723–39. 10.2165/00003495-200868120-00009
9. Ciprandi G, Varricchio A. The relevance of the mometasone furoate nasal spray in clinical practice. J Biol Regul Homeost Agents. 2018;32(4):1051–4.
10. Meltzer EO, Baena-Cagnani CE, Gates D, Teper A. Relieving nasal congestion in children with seasonal and perennial allergic rhinitis: Efficacy and safety studies of mometasone furoate nasal spray. World Allergy Organ J. 2013;6(1):5. 10.1186/1939-4551-6-5
11. Meltzer EO, Shekar T, Teper AA. Mometasone furoate nasal spray for moderate-to-severe nasal congestion in subjects with seasonal allergic rhinitis. Allergy Asthma Proc. 2011;32(2): 159–67. 10.2500/aap.2011.32.3424
12. Ciprandi G, Tosca MA, Passalacqua G, Canonica GW. Intranasal mometasone furoate reduces late-phase inflammation after allergen challenge. Ann Allergy Asthma Immunol. 2001; 86(4):433–8. 10.1016/S1081-1206(10)62491-X
13. Hoyte FCL, Nelson HS. Recent advances in allergic rhinitis. F1000 Res. 2018;7:F1000 Faculty Rev-1333. 10.12688/f1000research.15367.1
14. Karatzas K, Katsifarakis N, Riga M, Werchan B, Werchan M, Berger U, et al. New European Academy of Allergy and Clinical Immunology definition on pollen season mirrors symptom load for grass and birch pollen-induced allergic rhinitis. Allergy. 2018;73:1851–9. 10.1111/all.13487
15. Gelardi M, Fiorella ML, Russo C, Fiorella R, Ciprandi G. Role of nasal cytology. Int J Immunopathol Pharmacol. 2010;23 (Suppl 1):45–49.
16. Juniper EF, Guyatt GH, Feeny DH, Ferrie PJ, Griffith LE, Townsend M. Measuring quality of life in children with asthma. Qual Life Res. 1996;4:35–46. 10.1007/BF00435967
17. Benazzo M, Leonardi S, Corsico A, Licari A, Miraglia Del Giudice M, Peroni D, et al. Cetirizine modifies quality of life and symptoms in children with seasonal allergic rhinitis: A pilot study. Acta Biomed. 2020;92(1):e2021003.
18. Madison S, Brown EA, Franklin R, Wickersham EA, McCarthy LH. Clinical question: Nasal saline or intranasal corticosteroids to treat allergic rhinitis in children. J Okla State Med Assoc. 2016;109(4–5):152–3.
19. Gelardi M, Maselli del Giudice A, Candreva T, Fiorella ML, Allen M, Klersy K, et al. Nasal resistance and allergic inflammation depend on allergen type. Int Arch Allergy Immunol. 2006;141:384–9. 10.1159/000095465
20. D’Amato G, Holgate ST, Pawankar R, Ledford DK, Cecchi L, Al-Ahmad M, et al. Meteorological conditions, climate change, new emerging factors, and asthma and related allergic disorders. A statement of the World Allergy Organization. World Allergy Organ J. 2015;8(1):25. 10.1186/s40413-015-0073-0
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.